The Johns Hopkins University report identifies systemic gaps in NCD research, policy and practice Offering pragmatic actions and sustainable solutions, experts cite multisectoral cooperation as vital Independent research project stems from IFPMA Framework for Action on NCDs, focusing on innovation, access and affordability, prevention and health education, and partnerships The four main NCD categories –...
Read moreWHO Executive Board, 132nd session IFPMA Statement under agenda item 9.2 “Neglected Tropical Diseases” Delivered by Mario Ottiglio, Director, Public Affairs & Global Health Policy Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world Mr...
Read moreWHO Executive Board, 132nd session IFPMA Statement under agenda item 10.2 “Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination” Delivered by Mario Ottiglio, Director, Public Affairs & Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for the...
Read moreWHO Executive Board, 132nd session IFPMA Statement under agenda item 8.2 “Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits” Delivered by Janis Bernat, Assoc. Director, Biotherapeutics & Scientific Affairs Madam Chair, Madam Director General, and colleagues, thank you for the opportunity to provide input to this important discussion. The...
Read moreIFPMA Statement under agenda item 5: “Key issues for the development of a policy on engagement with NGOs” Delivered by Mario Ottiglio, Director, Public Affairs & Global Health Policy Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across...
Read moreReview shows 40 percent increase in R&D programs led by industry to find new or improved vaccines and treatments for ailments affecting more than one billion people R&D, health system capacity-strengthening efforts, and medicine donations comprise industry’s holistic approach to addressing neglected diseases Increased donations speed WHO’s ability to deliver medicines to people in need...
Read moreIFPMA Best wishes for the holiday season and a prosperous 2013
Read moreIndependent report developed by researchers at the University College London School of Pharmacy and the international research agency Matrix Insight A study released today highlights opportunities for a better coordinated international response to the threat of falsified, or counterfeit, medicines. The prevention of pharmaceutical falsification should be seen as an integral part of the global...
Read moreOpen-ended meeting of Member States on the follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) Delivered by Mario Ottiglio, Associate Director, Public Affairs & Global Health Policy Check against Delivery (26 November 2012) Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations...
Read more